Wang J, Cai L, Song Y, Sun T, et al. Clinical efficacy of fulvestrant versus exemestane as first-line therapies for Chinese postmenopausal oestrogen-receptor positive /human epidermal growth factor receptor 2 -advanced breast cancer (FRIEND study). Eur J Cancer 2023;184:73-82.
PMID: 36905771